Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

A Phase 2b Study of Selinexor in Combination with Pomalidomide in Patients with Pomalidomide-Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7070.

https://doi.org/10.1182/blood-2024-208473

Published: 2024

Journal Articles

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2024-208308

Published: 2024

Journal Articles

Repurposing DNA Methyltranferase Inhibitors As Epigenetic Priming Agents for T Cell Directed Therapies in Multiple Myeloma

Rena Feinman, Ariel Aptekmann, Iriana Colorado, Reilly Kobbe, Marta Salas, Noa Biran, David S. Siegel, Benjamin Tycko

Blood (2024) 144 (Supplement 1): 1888.

https://doi.org/10.1182/blood-2024-209229

Published: 2024

Journal Articles

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

Blood (2023) 142 (Supplement 1): 6714.

https://doi.org/10.1182/blood-2023-187011

Published: 2023

Journal Articles

Gut Microbiota Diversity and Composition Is Associated with High-Risk Myeloma

Rena Feinman, Ariel Aptekmann, Iriana Colorado, Samuel Roy, Katelyn Quino, Noreen Ahmed, Adolfo Aleman, Rashmi Unawane, Joshua Zenreich, Alana Barofsky, Kashish Bhatt, Michele L. Donato, Noa Biran, David S. Siegel

Blood (2023) 142 (Supplement 1): 3294.

https://doi.org/10.1182/blood-2023-190108

Published: 2023

Journal Articles

A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

Blood (2023) 142 (Supplement 1): 2022.

https://doi.org/10.1182/blood-2023-189907

Published: 2023

Journal Articles

Targeted Nanotherapy of Hematologic Malignancies Using Gold Nanoframework-Based Delivery of a Novel NF-Kb Inhibitor

Manpreet Bariana, Beilu Zhang, Jingyu Sun, Elena Cassella, Janice Rateshwar, Ming Tony Tan, Weiwei Wang, Jinping Wang, Rena Feinman, David Siegel, Hsiou-Chi Liou, Samedy Ouk, Patrizia Mondello, Hongjun Wang, Johannes Zakrzewski

Blood (2022) 140 (Supplement 1): 6018–6019.

https://doi.org/10.1182/blood-2022-160324

Published: 2022

Journal Articles

Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 4843–4844.

https://doi.org/10.1182/blood-2022-168934

Published: 2022

Journal Articles

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Jamie Koprivnikar, MD, James K McCloskey, MD, Rena Feinman, PhD, Robert Korngold, PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Themba Nyirenda, PhD, Andrew L. Pecora, MD

Blood (2019) 134 (Supplement_1): 5618.

https://doi.org/10.1182/blood-2019-132025

Published: 2019

Journal Articles

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Meena Bansal, DO, David S. Siegel, Jaeil Ahn, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Andrew L. Pecora, MD, Elli Gourna Paleoudis, PhD, Scott D. Rowley, MD, Michele L. Donato, MD, Robert Korngold, PhD, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 1911.

https://doi.org/10.1182/blood-2019-125155

Published: 2019

Journal Articles

Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Marshall McKenna, MD, Rena Feinman, PhD, Jaeil Ahn, PhD, Shuqi Wang, MSc, Elli Gourna Paleoudis, PhD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, Jun Chih Wang, MD, Abdul Rehman, MD, Giselle Alexandra Suero-Abreu, MD PhD, Phyllis McKiernan, Michele L. Donato, MD, Scott D. Rowley, MD, David S. Siegel, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 5510.

https://doi.org/10.1182/blood-2019-132134

Published: 2019

Journal Articles

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Alan P Skarbnik, MD, Michele L. Donato, MD, Robert Korngold, PhD, Rena Feinman, PhD, Scott D. Rowley, MD, Andre Goy, MD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, David S Siegel, MD PhD, Tatyana A. Feldman, MD, Noa Biran, MD, Lori A. Leslie, MD, Michael B Atkins, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 256.

https://doi.org/10.1182/blood-2018-99-113586

Published: 2018

Journal Articles

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Dante B. Descalzi-Montoya, PhD, Zheng Yang, MS, Kira Goldgirsh, MS, Rena Feinman, PhD, Stacey L. Fanning, PhD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, Michael B Atkins, MD, Scott D. Rowley, MD, Noa Biran, MD, David S Siegel, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Michele L. Donato, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 3421.

https://doi.org/10.1182/blood-2018-99-120240

Published: 2018

Journal Articles

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Rena Feinman, PhD, Tracy Andrews, MSc, Iriana Colorado, MSc, Joshua Zenreich, Suzanne Kosky, BS, Themba Nyirenda, PhD, Noa Biran, MD, David S Siegel, MD PhD, David H. Vesole, MD PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Pashna N. Munshi, MD, Michael B Atkins, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Andre Goy, MD, Robert Korngold, PhD, Alan P Skarbnik, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 3443.

https://doi.org/10.1182/blood-2018-99-117669

Published: 2018

Journal Articles

Evaluation of T Cell and Monocyte Immune Subsets in the Stem Cell Product of Patients Developing Engraftment Syndrome Following Autologous Stem Cell Transplantation for Multiple Myeloma and Lymphoma

Dante B. Descalzi-Montoya, PhD, Zheng Yang, MS, Kira Goldgirsh, MS, Rena Feinman, PhD, David S Siegel, MD PhD, Noa Biran, MD, David H. Vesole, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Scott D. Rowley, MD, Alan P Skarbnik, MD, Phyllis McKiernan, Melissa Baker, MSN, ANP, Michele L. Donato, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 4604.

https://doi.org/10.1182/blood-2018-99-120103

Published: 2018

Journal Articles

Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma and Lymphoma

Stacey L. Fanning, PhD, Kira Goldgirsh, MS, Dante B. Descalzi-Montoya, PhD, Rena Feinman, PhD, David S Siegel, MD PhD, Noa Biran, MD, David H. Vesole, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Scott D. Rowley, MD, Alan P Skarbnik, MD, Phyllis McKiernan, Melissa Baker, MSN, ANP, Michele L. Donato, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2018-99-118763

Published: 2018

Journal Articles

Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma

Dante Descalzi-Montoya, PhD, Kira Goldgirsh, MS, Zheng Yang, MS, Eugenia Dziopa, MS, Iriana Colorado, MS, Rena Feinman, PhD, Themba Nyirenda, PhD, David H. Vesole, MD, Pashna N. Munshi, MD, Scott D. Rowley, MD, Noa Biran, MD, Joshua R Richter, MD, David Siegel, MD PhD, Michele L. Donato, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2017) 130 (Supplement 1): 1862.

https://doi.org/10.1182/blood.V130.Suppl_1.1862.1862

Published: 2017

Journal Articles

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Noa Biran, MD, Tracy Andrews, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Joshua Zenreich, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Robert Korngold, PhD, David Siegel, MD PhD

Blood (2017) 130 (Supplement 1): 1831.

https://doi.org/10.1182/blood.V130.Suppl_1.1831.1831

Published: 2017

Journal Articles

Inhibition of HIF Prolyl Hydroxylases Mitigate Gut Graft-Versus-Host Disease

Rena Feinman, PhD, Iriana Colorado, MSc, Keyi Wang, MSc, Eugenia Dziopa, MSc, Michael A Flynn, MSc, Kevin Peters, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2016) 128 (22): 3349.

https://doi.org/10.1182/blood.V128.22.3349.3349

Published: 2016

Journal Articles

Intestinal Epithelial HIF-2 Is Protective in Gut Graft-Versus-Host-Disease

Rena Feinman, PhD, Iriana Colorado, MSc, Keyi Wang, BSc, Eugenia Dziopa, MSc, Leah Dziopa, MSc, Zheng Yang, MSc, Robert Korngold, PhD

Blood (2015) 126 (23): 1865.

https://doi.org/10.1182/blood.V126.23.1865.1865

Published: 2015

NARROW

A Phase 2b Study of Selinexor in Combination with Pomalidomide in Patients with Pomalidomide-Refractory Multiple Myeloma

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Repurposing DNA Methyltranferase Inhibitors As Epigenetic Priming Agents for T Cell Directed Therapies in Multiple Myeloma

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

Gut Microbiota Diversity and Composition Is Associated with High-Risk Myeloma

A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

Targeted Nanotherapy of Hematologic Malignancies Using Gold Nanoframework-Based Delivery of a Novel NF-Kb Inhibitor

Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Evaluation of T Cell and Monocyte Immune Subsets in the Stem Cell Product of Patients Developing Engraftment Syndrome Following Autologous Stem Cell Transplantation for Multiple Myeloma and Lymphoma

Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treatment of Multiple Myeloma and Lymphoma

Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Inhibition of HIF Prolyl Hydroxylases Mitigate Gut Graft-Versus-Host Disease

Intestinal Epithelial HIF-2 Is Protective in Gut Graft-Versus-Host-Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only